CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) Mechanical circulatory support devices in advanced heart failure: 2020 and beyond Readmission and Mortality After Hospitalization for Myocardial Infarction and Heart Failure Antithrombotics From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5) Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions Dilated cardiomyopathy: so many cardiomyopathies!

Guideline24 February 2021

JOURNAL:National Institue for Health and Care Excellence Article Link

Dapagliflozin for treating chronic heart failure with reduced ejection fraction

National Institue for Health and Care Excellence Keywords: HFrEF; guideline; NICE

Full Text PDF